filmov
tv
FcRn and the Long Half-Life of IgG Antibodies
Показать описание
A really important component of IgG antibodies is their ability to have a really long half-life in circulation, as opposed to other Ig subclasses.
Lower pH causes the IgG antibodies, not the IgM or IgE, but the IgG to bind to FcRn. They then are transported back up to the surface of the cell, and at neutral pH, are released back into circulation.
Lower pH causes the IgG antibodies, not the IgM or IgE, but the IgG to bind to FcRn. They then are transported back up to the surface of the cell, and at neutral pH, are released back into circulation.
0:02:00
FcRn and the Long Half-Life of IgG Antibodies
0:01:50
FcRn model platform
0:01:03
What is an FcRn Blocker and How Does It Work?
0:21:12
JAX Tech Talk #63: Let's talk FcRN: The Translational Platform for Antibody PK Assessment
0:01:16
About the FCRN
0:00:45
Impact of fcRn inhibitors on IgG-mediated autoimmune disorders
0:01:20
The Role of FcRn In More Than 100 Autoimmune Diseases
0:02:48
The use of the super albumin (QMP) technology for half-life extension of human coagulation factors.
0:53:46
Webinar: How can drug half-life extension improve patient care?
0:00:39
neonatal Fc receptor (English) - Medical terminology for medical students -
0:03:19
Albumin based Half life Extension
0:51:11
FcRn Affinity Column Chromatography for Therapeutic mAb Characterization
0:43:28
Strategies for Mitigating the Unpredictability of Fc-Mediated Functions in Antibody Development
0:39:01
Neonatal Fc Receptor in IgG-Mediated Autoimmune Disorders: Looking at a Common Denominator
0:43:44
Journal Club | Anti-FcRn Treatment in Antibody-Associated Experimental Autoimmune Encephalomyelitis
0:57:03
FcRn Modulation in Myasthenia Gravis: Applying the Evidence, Tools, and Patient Perspectives
0:01:46
Getting to know albumin physiology
0:02:11
QMP - Super Albumin Technology
0:03:05
Immunoglobulin crossing placenta / Ig G / Image based learning / Basic Immunology
0:11:45
Pharmacokinetics & Pharmacodynamics of Therapeutic Proteins Part 4 of 5 with Dr. Bernd Meibohm
0:04:05
Fc region of an antibody - What is it
0:01:32
cosMOG: anti-FcRn agent rozanolixizumab for relapse prevention in MOGAD
0:17:27
JAX Tech Talk, Episode 38: Let's Talk Pharmacokinetics for Antibody Development (15-June-2021)
0:20:04
FcRn Therapies 2021 Conference Humanized Cytokine Models
Комментарии